| Literature DB >> 25329197 |
Michael Y Bonner1, Jack L Arbiser.
Abstract
So-called antioxidants have yet to make a clinical impact on the treatment of human cancer. The reasons for this failure are several. First, many agents that are called antioxidants are truly antioxidants at a given dose, but this dose may not have been given in clinical trials. Second, many agents are not antioxidants at all. Third, not all tumors use reactive oxygen as a signaling mechanism. Finally, reactive oxygen inhibition is often insufficient to kill or regress a tumor cell by itself, but requires sequential introduction of a therapeutic agent for maximal effect. We hope to provide a framework for the logical use of these agents in cancer.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25329197 PMCID: PMC4412352 DOI: 10.4155/fmc.14.86
Source DB: PubMed Journal: Future Med Chem ISSN: 1756-8919 Impact factor: 3.808